This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License.
Ahn JY, Ann HW, Jeon Y, Ahn MY, Oh DH, Kim YC, Kim EJ, Song JE, Jung IY, Kim MH, et al. 2017. The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea. BMC Infect Dis. 17:327.AhnJYAnnHWJeonYAhnMYOhDHKimYCKimEJSongJEJungIYKimMH2017The impact of production of extended-spectrum β-lactamases on the 28-day mortality rate of patients with Proteus mirabilis bacteremia in Korea1732710.1186/s12879-017-2431-8541571128468622Search in Google Scholar
Armbruster CE, Mobley HLY. 2012. Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis. Nat Rev Microbiol. 10(11):743–754.ArmbrusterCEMobleyHLY2012Merging mythology and morphology: the multifaceted lifestyle of Proteus mirabilis10(11):74375410.1038/nrmicro2890362103023042564Search in Google Scholar
CLSI. 2009. Performance Standards for Antimicrobial Disk Susceptibility Tests. 11th ed. CLSI standard M02. Wayne (USA): Clinical and Laboratory Standards Institute.CLSI2009Performance Standards for Antimicrobial Disk Susceptibility Tests11th ed.Wayne (USA)Clinical and Laboratory Standards InstituteSearch in Google Scholar
Di Domenico EG, Farulla I, Prignano G, Gallo MT, Vespaziani M, Cavallo I, Sperduti I, Pontone M, Bordignon V, Cilli L, et al. 2017. Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype. Internat J Mol Sci, 18(5):1077.Di DomenicoEGFarullaIPrignanoGGalloMTVespazianiMCavalloISperdutiIPontoneMBordignonVCilliL2017Biofilm is a major virulence determinant in bacterial colonization of chronic skin ulcers independently from the multidrug resistant phenotype18(5):107710.3390/ijms18051077545498628513576Search in Google Scholar
Di Pilato V, Chiarelli A, Boinett CJ, Riccobono E, Harris SR, D’Andrea M, Thomson NR, Rossolini GM, Giani T. 2016. Complete genome sequence of the first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream infection. Genome Announc. 4(3):e00607–16.Di PilatoVChiarelliABoinettCJRiccobonoEHarrisSRD’AndreaMThomsonNRRossoliniGMGianiT2016Complete genome sequence of the first KPC-type carbapenemase-positive Proteus mirabilis strain from a bloodstream infection4(3):e00607–1610.1128/genomeA.00607-16491941127340072Search in Google Scholar
Drzewiecka D. 2016. Significance and roles of Proteus spp. bacteria in natural environments. Microb Ecol. 72(4):741–758.DrzewieckaD2016Significance and roles of Proteus spp. bacteria in natural environments72(4):74175810.1007/s00248-015-0720-6508032126748500Search in Google Scholar
Endimiani A, Luzzaro F, Brigante G, Perilli M, Lombardi G, Amicosante G, Rossolini GM, Toniolo A. 2005. Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases. Antimicrob Agents Chemother. 49:2598–2605.EndimianiALuzzaroFBriganteGPerilliMLombardiGAmicosanteGRossoliniGMTonioloA2005Proteus mirabilis bloodstream infections: risk factors and treatment outcome related to the expression of extended-spectrum beta-lactamases492598260510.1128/AAC.49.7.2598-2605.2005116871415980325Search in Google Scholar
EUCAST. 2016. Breakpoint tables for interpretation of MICs and zone diameters, version 8.0 [Internet]. London (UK): The European Committee on Antimicrobial Susceptibility Testing; [cited 2018 June 27]. Available from http://www.eucast.org/clinical_breakpoints/EUCAST2016London (UK)The European Committee on Antimicrobial Susceptibility Testing;[cited 2018 June 27]. Available from http://www.eucast.org/clinical_breakpoints/Search in Google Scholar
Kim BN, Kim NJ, Kim MN, Kim YS, Woo JH, Ryu J. 2003. Bacteremia due to tribe Proteeae: a review of 132 cases during a decade (1991–2000). Scand J Infect Dis. 35(2):98–103.KimBNKimNJKimMNKimYSWooJHRyuJ2003Bacteremia due to tribe Proteeae: a review of 132 cases during a decade (1991–2000)35(2):9810310.1080/003655402100002701512693558Search in Google Scholar
Kwiecińska-Piróg J, Bogiel T, Gospodarek E. 2013a. Effects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods. J Antibiot. 66(10):593–597.Kwiecińska-PirógJBogielTGospodarekE2013aEffects of ceftazidime and ciprofloxacin on biofilm formation in Proteus mirabilis rods66(10):59359710.1038/ja.2013.5923801185Search in Google Scholar
Kwiecińska-Piróg J, Skowron K, Zniszczoł K, Gospodarek E. 2013b. The assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms. Biomed Res Int. 2013:1–8.Kwiecińska-PirógJSkowronKZniszczołKGospodarekE2013bThe assessment of Proteus mirabilis susceptibility to ceftazidime and ciprofloxacin and the impact of these antibiotics at subinhibitory concentrations on Proteus mirabilis biofilms20131810.1155/2013/930876378758624151628Search in Google Scholar
Laupland KB, Church DL. 2014. Populations-based epidemiology and microbiology of community-onset bloodstream infections. Clin Microbiol Rev. 27:647–664.LauplandKBChurchDL2014Populations-based epidemiology and microbiology of community-onset bloodstream infections2764766410.1128/CMR.00002-14418763325278570Search in Google Scholar
Laupland KB, Parkins MD, Ross T, Pitout JDD. 2007. Population-based laboratory surveillance for tribe Proteeae isolates in a large Canadian health region. Clin Microbiol Infect. 13(7):683–688.LauplandKBParkinsMDRossTPitoutJDD2007Population-based laboratory surveillance for tribe Proteeae isolates in a large Canadian health region13(7):68368810.1111/j.1469-0691.2007.01715.x17403132Search in Google Scholar
Lebeaux D, Ghigo JM, Beloin C. 2014. Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics. Microbiol Mol Biol Rev. 78(3):510–543.LebeauxDGhigoJMBeloinC2014Biofilm-related infections: bridging the gap between clinical management and fundamental aspects of recalcitrance toward antibiotics78(3):51054310.1128/MMBR.00013-14418767925184564Search in Google Scholar
O’Hara CM, Brenner FW, Miller JM. 2000. Classification, identification and clinical significance of Proteus, Providencia, and Morganella. Clin Microbiol Rev. 13(4):534–546.O’HaraCMBrennerFWMillerJM2000Classification, identification and clinical significance of Proteus, Providencia, and Morganella13(4):53454610.1128/CMR.13.4.5348894711023955Search in Google Scholar
Różalski A, Kwil I, Torzewska A, Baranowska M, Stączek P. 2007. Proteus bacilli: features and virulence factors. Post Hig Med Dosw. 61:204–219.RóżalskiAKwilITorzewskaABaranowskaMStączekP2007Proteus bacilli: features and virulence factors61204219Search in Google Scholar
Sabbuba NA, Mahenthiralingam E, Stickler DJ. 2003. Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract. J Clin Microbiol. 41(11):4961–4965.SabbubaNAMahenthiralingamESticklerDJ2003Molecular epidemiology of Proteus mirabilis infections of the catheterized urinary tract41(11):4961496510.1128/JCM.41.11.4961-4965.200326249714605124Search in Google Scholar
Sohn KM, Kang ChI, Joo EJ, Ha YE, Chung DR, Peck KR, Lee NY, Song JH. 2011. Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Proteus mirabilis bacteriemia. Korean J Intern Med. 26:89–93.SohnKMKangChIJooEJHaYEChungDRPeckKRLeeNYSongJH2011Epidemiology of ciprofloxacin resistance and its relationship to extended-spectrum beta-lactamase production in Proteus mirabilis bacteriemia26899310.3904/kjim.2011.26.1.89305626221437168Search in Google Scholar
Tumbarello M, Trecarichi EM, Fiori B, Losito AR, D’Inzeo T, Campana L, Ruggeri A, Di Meco E, Liberto E, Fadda G, et al. 2012. Multidrug-Resistant Proteus mirabilis bloodstream infections: risk factors and outcomes. Antimicrob Agents Chemother. 56(6):3224–3231.TumbarelloMTrecarichiEMFioriBLositoARD’InzeoTCampanaLRuggeriADi MecoELibertoEFaddaG2012Multidrug-Resistant Proteus mirabilis bloodstream infections: risk factors and outcomes56(6):3224323110.1128/AAC.05966-11337081522450979Search in Google Scholar
Wang JT, Chen PC, Chang SC, Shiau YR, Wang HY, Lai JF, Huang IW, Tan MC, Lauderdale TL. 2014. TSAR Hospitals. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program. BMC Infec Dis. 14(1):486.WangJTChenPCChangSCShiauYRWangHYLaiJFHuangIWTanMCLauderdaleTL2014TSAR Hospitals. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program14(1):48610.1186/1471-2334-14-486416295025192738Search in Google Scholar
Watanakunakorn C, Perni SC. 1994. Proteus mirabilis bacteremia: a review of 176 cases during 1980–1992. Scand J Infect Dis. 26:361–367.WatanakunakornCPerniSC1994Proteus mirabilis bacteremia: a review of 176 cases during 1980–19922636136710.3109/003655494090086057984964Search in Google Scholar